Improving shoulder range of motion (ROM), including functional internal rotation (fIR) after reverse shoulder arthroplasty (RSA), is crucial for the patient’s daily activity. We aimed to investigate the potential differences in shoulder ROM and fIR after RSA based on the glenosphere size (36 mm vs. 39 mm) and to evaluate if increasing the glenosphere size affects shoulder ROM and fIR. A retrospective analysis was performed on patients who had RSA with a minimum follow-up of 2 years postoperatively. A 36 mm or 39 mm glenosphere was utilized based on surgeon preference. Functional outcomes were evaluated using the constant score (CS) and simple shoulder value (SSV). Shoulder ROM assessment included evaluating passive and active external rotation (ER) and forward elevation, while fIR was assessed and classified into type I if the hand was blocked to the buttock, type II lumbar sliding, and type III smooth motion. Type I was non-functional, while types II and III were functional. A total of 222 patients were eligible for inclusion, having a mean age of 72 ± 8 years; 109 had a glenosphere 36 mm (Group 1), and 113 had a glenosphere 39 mm (Group 2). After a mean follow-up of 24.7 ± 4.1 months, the overall CS significantly improved from 42.8 ± 15.3 preoperatively to 73.4 ± 11.8 at the last follow-up (p < 0.01), and the SSV increased from 43.6 ± 16.7 to 79.7 ± 13.2 (p < 0.01), however, patients in group 2 had higher values in the strength component of the Constant Score (11.4 ± 6.1 vs. 8.7 ± 4.7, p < 0.01) and better active ER (29.6 ± 19.8 vs. 22.2 ± 20.7, p < 0.01), with no significant difference in the remaining parameters. Functional categories (Type II or III at last follow-up) of fIR were achieved in 79 (72.5
DAROL is an ongoing study of real-world safety and effectiveness of darolutamide in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). This prespecified interim analysis included 550 patients with nmCRPC who completed ≥6 months of treatment with darolutamide 600 mg twice daily. Darolutamide showed consistent safety and effectiveness in DAROL vs ARAMIS. Most treatment-emergent adverse events were grade 1/2. Two-year overall survival and metastasis-free survival rates and prostate-specific antigen responses were similar to ARAMIS. These findings indicate that darolutamide offers effectiveness and a favorable safety profile in the broad range of patients seen in clinical practice.
Achondroplasia is a common skeletal dysplasia with a high prevalence of obesity in adulthood. Bariatric surgery has been shown to be effective in treating obesity and related comorbidities, but its feasibility and effectiveness in patients with achondroplasia have not been clearly established. The objective of this study was to evaluate the feasibility and effectiveness of bariatric surgery in patients with achondroplasia. This study was performed in France, and bariatric surgeons from the Société Française et Francophone de Chirurgie de l'Obésité et des Maladies Métaboliques (French Francophone Society of Surgery for Obesity or Metabolic Diseases) were asked to participate. Two adult women with confirmed achondroplasia and a high BMI were selected for laparoscopic sleeve gastrectomy. Preoperative data were collected, including demographic information, comorbidities, and follow-up at 1, 3, and 6 months and 1 year after surgery. Complications were monitored and recorded. Both patients had good excess weight loss outcomes, with an average excess weight loss of 60.5
471 Background: In the phase 3 JAVELIN Bladder 100 trial, avelumab 1L maintenance + best supportive care (BSC) significantly prolonged overall survival (OS) vs BSC alone in pts with aUC that had not progressed with 1L platinum-based chemotherapy (CTx). The JAVELIN Bladder regimen is now standard of care with level 1 evidence in international treatment guidelines. The AVENANCE study (NCT04822350), is investigating the efficacy and safety of avelumab 1L maintenance in a real-world population of pts with aUC in France. Data from the full analysis set are reported for the first time. Methods: In this ongoing, noninterventional, ambispective study, eligible pts have locally advanced or metastatic UC that has not progressed with 1L platinum-based CTx and previous, ongoing, or planned avelumab 1L maintenance treatment. The primary endpoint is OS from start of avelumab; secondary endpoints include progression-free survival (PFS), duration of treatment (DOT), and safety. Results: 591 pts received avelumab. At data cutoff (July 31, 2022), median follow-up was 12.0 mo (95% CI, 10.9-12.9). Median age was 73.1 y (IQR, 67.0-78.1). At start of 1L CTx (excluding pts with missing data), disease stage was metastatic in 524 pts (90.5%; visceral metastases in 426 [81.5%]) and locally advanced in 54 (9.3%). ECOG PS was 0-1 in 407 pts (85.3%) and 2-3 in 69 (14.5%). Tumor histology was pure UC in 528 pts (91.8%) and UC with variant or pure variant in 47 (8.2%). 1L CTx was gemcitabine + carboplatin (GemCarbo), gemcitabine + cisplatin (GemCis), dose-dense methotrexate + vinblastine + adriamycin + cisplatin (DD-MVAC), and other in 353 (61.0%), 170 (29.4%), 28 (4.8%), and 28 (4.8%) pts, respectively. Median number of cycles was 5 (range, 1-10). Median DOT with avelumab was 5.8 mo (95% CI, 5.2-7.0); 241 pts (40.8%) remained on treatment at data cutoff. The most common reasons for treatment discontinuation were disease progression (74.1% [n=258]), death (11.5% [n=40]), and adverse events ([AEs] 10.3% [n=36]). Median OS from start of avelumab was 18.4 mo (95% CI, 15.4-not estimable [NE]), the 12-month OS rate was 64.8% (95% CI, 60.0%-69.1%), and median PFS was 5.7 mo (95% CI, 5.3-7.0). In pts who had received GemCarbo, GemCis, or DD-MVAC, median OS (95% CI) was 16.2 mo (13.4-NE), not reached (NR; 18.1-NE), and NR (15.2-NE), respectively. Subgroups analyses will be presented. 218 pts received subsequent 2L, including CTx, antibody-drug conjugates, immunotherapy, and other in 186 (85.3%), 22 (10.1%), 6 (2.8%), and 4 (1.8%) pts, respectively. Any-grade treatment-related AEs (TRAEs) occurred in 217 pts (36.7%), including serious TRAEs in 29 (4.9%). Conclusions: Real-world data for avelumab 1L maintenance in pts with aUC from AVENANCE support the findings of JAVELIN Bladder 100 and confirm the clinical activity and acceptable safety profile of avelumab in a heterogeneous population. Clinical trial information: NCT04822350 .
Background: There is little overall evidence behind clinical practice guidelines for diagnosis and treatment of rotator cuff repair. The purpose was to compare the accuracy of different machine learning models that use pre-operative data from an international and multicentric database to predict if a patient that underwent rotator cuff repair, could achieve the minimal important change (MIC) for single assessment numeric evaluation (SANE) at one year follow-up.Methods: This study analyzed prospectively collected data of patients undergoing rotator cuff repair. In total, 4683 cases were enrolled and divided into the training (80%) and validation (20%) datasets. Different machine learning models were trained (Extreme Gradient Boosting [XGBoost], Support Vector Machine [SVM], Multi-Layer Perceptron [MLP]), tested and compared using 229 valid pre-operative variables with a specificity set at 95%. The top ten features with the highest impact on the model output were then identified through SHapley Additive exPlanations (SHAP) and used to develop a simplified model. Privileged and unprivileged groups were designated to perform an exploratory fairness analysis.Findings: The performance of the best performing model (XGBShap10) revealed a precision of 0×587 (0×485-0×685), a recall of 0×320 (0×252-0×392), a balanced accuracy of 0×636 (0×593-0×679), a F1 -score of 0×413 (0×338-0×487), and an area under the receiver operating characteristic curve (AUC) of 0×667 (0×618-0×715).Interpretation: The present ML model performance was limited with a balanced accuracy of 64%. However, this model enabled the detection of one third of RCR failures. Using this model in clinical practice would theoretically avoid 4×4% of unnecessary operations while accepting to leave aside 5% of appropriate candidates for surgery.Funding: This project has received funding from the Fondation de Bienfaisance Pierre & Andrée Haas (Geneva, Switzerland), the insurance Foundation Groupe Mutuel (Martigny, Switzerland), FORE (Foundation for Research and Teaching in Orthopedics, Sports Medicine, Trauma, and Imaging in the Musculoskeletal System), Grant #2023-13, and TheArk Foundation (Valais, Switzerland).Declaration of Interest: Alexandre Lädermann is a paid consultant for Arthrex, Stryker, Medacta, and Enovis. He received royalties from Stryker and Medacta. He is the (co)founder of FORE, Med4Cast, and BeeMed. Philippe Collin receives royalties from and is a consultant and paid speaker for Stryker and Enovis. He is the co-founder of Med4Cast and Follow. He is on the board of SECEC and IBSES. Patrick Denard receives royalties from and is a consultant and paid speaker for Arthrex. He is the co-founder of Med4Cast. All others have nothing to declare. Ethical Approval: The registry used in this study as well as the research protocol were approved by ethical review boards (SOS #1) and ethics committee (EKNZ #2019-02076, CCER #2020-02670, Pred cohort study17) and registered at ClinicalTrials.gov (identifier NCT06145815) and at Registry of all Projects in Switzerland (RAPS identifier CCER 2020-02670). Every patient enrolled in this open-label clinical database provided a written informed consent for the use of their data.